An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification.
about
Generation of Soluble Interleukin-11 and Interleukin-6 Receptors: A Crucial Function for Proteases during InflammationStrategies to design and analyze targeted sequencing data: cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium Targeted Sequencing StudyFunctional IL6R 358Ala allele impairs classical IL-6 receptor signaling and influences risk of diverse inflammatory diseasesGenetic modulation of the interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy.Impact of interleukin-6 in hematological malignancies.Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levelsThe contribution of the functional IL6R polymorphism rs2228145, eQTLs and other genome-wide SNPs to the heritability of plasma sIL-6R levels.Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studiesGenetic and environmental determinants of population variation in interleukin-6, its soluble receptor and C-reactive protein: insights from identical and fraternal twins.Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium.Paclitaxel-Fe3O4 nanoparticles inhibit growth of CD138(-) CD34(-) tumor stem-like cells in multiple myeloma-bearing mice.Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche.Interleukin-6 polymorphisms and hematologic malignancy: a re-appraisal of evidence from genetic association studies.Targeting classical IL-6 signalling or IL-6 trans-signalling in depression?Mendelian Randomization Analyses for Selection of Therapeutic Targets for Cardiovascular Disease Prevention: a Note of Circumspection.Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.The relationship between soluble receptor of interleukin-6 with angiogenic cytokines and proliferation markers in multiple myeloma.Do baseline Cereblon gene expression and IL-6 receptor expression determine the response to thalidomide-dexamethasone treatment in multiple myeloma patients?Immune-suppressive effects of interleukin-6 on T-cell-mediated anti-tumor immunity.ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma.Clinical impact of serum soluble SLAMF7 in multiple myeloma
P2860
Q26738992-F5339C2E-6B95-4609-8C08-1F5EA46235BBQ28655423-82A0B35B-F7D2-44FC-8A29-ABD2A54643EEQ30419941-9908000B-B537-4DF8-B9B9-D4E61D7D465AQ33714950-514F8050-E2ED-4EE4-943B-489D7A345D63Q34387624-1B989A54-8B8A-4004-B579-0FE370F83690Q34571230-C5635916-0D1E-47EC-AD07-B22EF78030B0Q34811998-8B39260E-E872-45F8-A9B8-D08E934E0ADAQ35863952-A4811940-9EB5-42DC-94CB-1BA627388BE1Q36053056-096803C3-6B60-4143-882A-77DF6292DF84Q36474567-CCDD0A24-80EB-4597-8725-B02BDEC0D977Q36776906-8278A88D-F841-4F97-B49E-EA72AF17C8EBQ37636576-0ADCD5B7-EBAF-4F4E-8580-3F27B227791BQ38141145-4AC4DE21-D5EA-49CF-A544-7E6D775CBEA2Q38189135-44921221-2C75-4A1D-B860-3B838F8251FFQ38707328-FF83552A-A08F-44FD-9521-B7FD2FCE225AQ38960661-D276A1D4-6D25-4919-8795-626387FDC900Q44585463-04E3EE7C-5F20-435D-8062-68AD054ED812Q46256449-58B47069-FBDE-44F8-BF01-A44EBAF3A81EQ48090319-74BD14D9-29F4-4E5E-8F4B-768A4CB24115Q50912108-D435331C-4641-4188-AD9F-B3ED07B0F567Q58582611-FE85B17E-3B14-4F45-9432-0CBE2D684C75
P2860
An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
An intermediate-risk multiple ...... 228145 and 1q21 amplification.
@ast
An intermediate-risk multiple ...... 228145 and 1q21 amplification.
@en
type
label
An intermediate-risk multiple ...... 228145 and 1q21 amplification.
@ast
An intermediate-risk multiple ...... 228145 and 1q21 amplification.
@en
prefLabel
An intermediate-risk multiple ...... 228145 and 1q21 amplification.
@ast
An intermediate-risk multiple ...... 228145 and 1q21 amplification.
@en
P2093
P2860
P1433
P1476
An intermediate-risk multiple ...... 228145 and 1q21 amplification.
@en
P2093
David R Williams
Erming Tian
John D Shaughnessy
Joshua Epstein
Owen W Stephens
Pingping Qu
Qing Zhang
Shweta Chavan
Yiming Zhou
P2860
P304
P356
10.1182/BLOOD-2011-07-367052
P407
P577
2011-11-09T00:00:00Z